How tumor genetics affect immune responses in pancreatic cancer treatment
Project 3: Impact of tumor genetics on PDAC immunobiology and responses to macrophage-targeted immunotherapy
This study is looking at how the genes of pancreatic cancer tumors affect the immune system around them, which could help us understand why some treatments don’t work and lead to better therapies for patients battling this tough cancer.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10927305 on NIH RePORTER |
What this research studies
This research investigates the role of tumor genetics in shaping the immune environment of pancreatic ductal adenocarcinoma (PDAC), a challenging cancer to treat. By examining how different genetic mutations and the origin of tumor cells influence the presence and behavior of immune cells, particularly macrophages, the study aims to uncover new insights into treatment resistance. The researchers will utilize advanced techniques to analyze immune cell distribution and function in specially designed mouse models that mimic human PDAC. This approach could lead to better-targeted immunotherapies for patients with this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with specific genetic mutations.
Not a fit: Patients with other types of cancer or those without pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy strategies for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Engleman, Edgar G. — Stanford University
- Study coordinator: Engleman, Edgar G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.